| Literature DB >> 33215691 |
Sebastian Schnaubelt1, Arnold Pilz2, Lorenz Koller3, Niema Kazem3, Felix Hofer3, Tatjana Fleck4, Günther Laufer4, Barbara Steinlechner5, Alexander Niessner3, Patrick Sulzgruber3.
Abstract
BACKGROUND: Post-operative atrial fibrillation (POAF) represents a common complication after cardiac valve or coronary artery bypass surgery. While strain of atrial tissue is known to induce atrial fibrillating impulses, less attention has been paid to potentially strain-promoting values during the peri- and post-operative period. This study aimed to determine the association of peri- and post-operative volume substitution with markers of cardiac strain and subsequently the impact on POAF development and promotion.Entities:
Keywords: atrial fibrillation; cardiac strain; cardiac surgery; volume substitution
Mesh:
Substances:
Year: 2020 PMID: 33215691 PMCID: PMC8244026 DOI: 10.1111/eci.13456
Source DB: PubMed Journal: Eur J Clin Invest ISSN: 0014-2972 Impact factor: 4.686
Baseline characteristics
| Total study population (n = 271) | POAF (n = 123) | Non‐POAF (n = 148) |
| |
|---|---|---|---|---|
| Clinical characteristics | ||||
| Age, years (IQR) | 69 (60‐75) | 72 (66‐76) | 65 (57‐73) |
|
| Male gender, n (%) | 195 (72.0) | 79 (64.2) | 116 (78.4) |
|
| BMI, kg/m2 (IQR) | 27.1 (24.5‐30.4) | 27.6 (24.5‐31.2) | 27.1 (24.5‐29.9) | .249 |
| SBP at admission, mm Hg (IQR) | 130 (118‐140) | 130 (116‐142) | 130 (119‐140) | .974 |
| DBP at admission, mm Hg (IQR) | 71 (63‐80) | 70 (62‐80) | 71 (65‐82) | .119 |
| Heart rate at admission, bpm | 70 (63‐80) | 70 (63‐80) | 70 (63‐80) | .566 |
| Cardiac diseases and comorbidities | ||||
| Smoking history, n (%) | 152 (56.1) | 63 (51.2) | 89 (60.1) | .084 |
| Coronary vessel disease, n (%) | 161 (59.4) | 77 (62.6) | 84 (56.8) | .353 |
| Valve disease, n (%) | 194 (71.6) | 95 (77.2) | 99 (66.9) | .067 |
| CAD and valve disease, n (%) | 87 (32.1) | 49 (39.8) | 38 (25.7) |
|
| Previous MI, n (%) | 69 (25.5) | 34 (27.6) | 35 (23.6) | .492 |
| Previous stroke or TIA, n (%) | 25 (9.2) | 8 (6.5) | 17 (11.5) | .158 |
| Hypertension, n (%) | 222 (81.9) | 104 (84.6) | 118 (79.7) | .339 |
| Type II Diabetes Mellitus, n (%) | 85 (31.4) | 43 (35.0) | 42 (28.4) | .260 |
| COPD | 37 (13.7) | 20 (16.3) | 17 (11.5) | .254 |
| Chronic kidney disease, n (%) | 40 (14.8) | 27 (22.0) | 13 (8.8) |
|
| Pre‐operative laboratory values (at admission) | ||||
| Creatinine, mg/dL (IQR) | 0.94 (0.79‐1.18) | 0.98 (0.79‐1.30) | 0.93 (0.79‐1.08) |
|
| Cholesterol, mg/dL (IQR) | 164 (133‐195) | 165 (136‐191) | 163 (126‐198) | .752 |
| Triglycerides, mg/dL (IQR) | 116 (79‐156) | 115 (78‐152) | 117 (82‐162) | .628 |
| HbA1c, % (IQR) | 5.6 (5.2‐6.4) | 5.7 (5.3‐6.4) | 5.6 (5.2‐6.1) | .465 |
| Haemoglobin, mg/dL (IQR) | 13.4 (12.1‐14.4) | 13.0 (11.6‐14.3) | 13.6 (12.4‐14.7) |
|
| Leukocytes, 109/L (IQR) | 7.15 (6.02‐8.45) | 7.09 (5.64‐8.44) | 7.17 (6.25‐8.68) | .157 |
| CRP, mg/dL (IQR) | 0.22 (0.09‐0.51) | 0.26 (0.12‐0.49) | 0.17 (0.07‐0.52) | .053 |
| NT‐proBNP, pg/mL (IQR) | 466 (197‐1622) | 809 (363‐2154) | 332 (150‐840) |
|
| Troponin T, ng/mL(IQR) | 0.02 (0.01‐0.05) | 0.04 (0.02‐0.09) | 0.02 (0.01‐0.04) | .244 |
| Post‐operative laboratory parameters (ICU) | ||||
| Leukocytes, 109/L (IQR) | 14.0 (10.6‐18.5) | 13.9 (10.5‐17.9) | 14.1 (10.7‐19.2) | .370 |
| Maximum CRP, mg/dL (IQR) | 19.6 (14.3‐23.3) | 19.5 (14.4‐23.1) | 19.7 (14.2‐23.8) | .865 |
| NT‐proBNP, pg/mL (IQR) | 1940 (940‐3736) | 2572 (1504‐5903) | 1364 (703‐2374) |
|
| Chronic cardiac medication | ||||
| Beta‐blockers, n (%) | 154 (56.8) | 78 (63.4) | 76 (51.4) |
|
| ACE‐inhibitors, n (%) | 104 (38.4) | 50 (40.7) | 54 (36.5) | .483 |
| ARB, n (%) | 76 (28.0) | 37 (30.1) | 39 (26.4) | .496 |
| Diuretics, n (%) | 75 (27.7) | 42 (34.1) | 33 (22.3) |
|
| Statins, n (%) | 171 (63.1) | 77 (62.6) | 94 (63.5) | .877 |
| Digitoxin, n (%) | 1 (0.4) | 0 (0.0) | 1 (0.7) | .361 |
Categorical data are presented as counts and percentages, continuous data as medians and interquartile ranges (IQR). Mann‐Whitney U test and chi‐square test were used to assess differences between subgroups.
Abbreviations: ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; bpm, beats per minute; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRP, C‐reactive protein; HbA1c, haemoglobin A1c; MI, myocardial infarction; mmHg, millimetres mercury; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; TIA, transistoric ischaemic attack.
Bold values are indicates significant p‐values.
Fluid management
| Total study population (n = 271) | POAF (n = 123) | Non‐POAF (n = 148) |
| |
|---|---|---|---|---|
| Any transfusion received, n (%) | 131 (48.3) | 74 (60.2) | 57 (38.5) |
|
| Total transfusion volume, mL (IQR) | 378.0 (291.3‐464.7) | 605.6 (453.3‐757.8) | 227.1 (163.6‐290.5) |
|
| ICU 24 h fluid balance, mL (IQR) | 780.0 (220.5‐1992.5) | 1129.6 (406.0‐2336.8) | 544.9 (176.9‐1497.0) |
|
| Red blood cell transfusion, n (%) | 118 (43.5) | 71 (57.7) | 47 (31.8) |
|
| Platelet transfusion, n (%) | 37 (13.7) | 21 (17.1) | 16 (10.8) | .135 |
| Fresh frozen plasma transfusion, n (%) | 10 (3.7) | 9 (7.3) | 1 (0.7) | .004 |
| Fibrinogen, n (%) | 77 (28.4) | 41 (33.3) | 36 (24.3) | .102 |
| Antithrombin III, n (%) | 18 (6.6) | 10 (8.1) | 8 (5.4) | .370 |
| Prothrombin complex concentrate, n (%) | 27 (10.0) | 18 (14.6) | 9 (6.1) |
|
| Desmopressin, n (%) | 17 (6.3) | 9 (7.3) | 8 (5.4) | .518 |
Categorical data are presented as counts and percentages, continuous data as medians and interquartile ranges (IQR). Mann‐Whitney U test and chi‐square test were used to assess differences between subgroups. Any transfusion received and total transfusion volume summarizes red blood cell, platelet and fresh frozen plasma transfusions.
Abbreviation: ICU, intensive care unit.
Bold values are indicates significant p‐values.
Regression analyses for POAF occurrence
| Crude OR (95% CI) |
|
|
| |
|---|---|---|---|---|
| Total transfusion volume | 1.46 (1.18‐1.81) |
| 1.44 (1.09‐1.31) |
|
Logistic regression model for the association of total transfusion volume (mL) and the development of POAF.
The multivariate model was adjusted for gender, age, body mass index, chronic kidney disease, coronary artery disease, valve disease, extracorporal circulation time and aortic clamp time. All continuous data were log‐transformed prior to analysis. Odds ratios (OR) and the respective confidence intervals (CI) refer to a risk increase per one litre of transfusion volume.
Bold values are indicates significant p‐values.